The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation

European Journal of Pharmacology

Volumn 648, Issue 1-3, 2010, Pages 59-66

  Tang, Chih Hsin ^a   Chang, Chih Shiang ^a   Tan, Tzu Wei ^a   Liu, Shan Chi ^b   Liu, Ju Fang ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Chinese herb; Isoflavones; Osteoclast; Osteoporosis; RANKL

Indexed keywords

5,7 DIHYDROXY 3 [4' (4 CHLOROBENZOYL)AMINO]ISOFLAVONE; 5,7 DIHYDROXY 3 [4' (4 METHOXYBENZOYL)AMINO]ISOFLAVONE; 5,7 DIHYDROXY 3 [4' (BENZYL)AMINO]ISOFLAVONE; 5,7 DIHYDROXY 3 [4' (DIBENZOYL)AMINO]ISOFLAVONE; 5,7 DIHYDROXY 3 [4' (ISONICOTINOYL)AMINO]ISOFLAVONE; COLONY STIMULATING FACTOR 1; ISOFLAVONE DERIVATIVE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA PROTEIN COMPLEX; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MACROPHAGE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RAT; STROMA CELL;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL LINE; ENZYME ACTIVATION; FEMALE; HUMANS; ISOFLAVONES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; NF-KAPPA B; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; STROMAL CELLS;

EID: 77957753272     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.052     Document Type: Article

References (35)

1. Arjmandi B.H., Alekel L., Hollis B.W., Amin D., Stacewicz-Sapuntzakis M., Guo P., Kukreja S.C. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J. Nutr. 1996, 126:161-167.
2. Bahr J.M., Nakai M., Rivera A., Walsh J., Evans G.L., Lotinun S., Turner R.T., Black M., Jeffery E.H. Dietary soy protein and isoflavones: minimal beneficial effects on bone and no effect on the reproductive tract of sexually mature ovariectomized Sprague-Dawley rats. Menopause 2005, 12:165-173.
3. Berg C., Neumeyer K., Kirkpatrick P. Teriparatide. Nat. Rev. Drug Discov. 2003, 2:257-258.
4. Brown M.D., Sacks D.B. Protein scaffolds in MAP kinase signalling. Cell. Signal. 2009, 21:462-469.
5. Chen X., Garner S.C., Quarles L.D., Anderson J.J. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J. Nutr. Biochem. 2003, 14:342-349.
6. Darnay B.G., Aggarwal B.B. Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann. Rheum. Dis. 1999, 58(Suppl 1):I2-I13.
7. Darnay B.G., Haridas V., Ni J., Moore P.A., Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J. Biol. Chem. 1998, 273:20551-20555.
8. Darnay B.G., Ni J., Moore P.A., Aggarwal B.B. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem. 1999, 274:7724-7731.
9. Deal C. Future therapeutic targets in osteoporosis. Curr. Opin. Rheumatol. 2009, 21:380-385.
10. Draper C.R., Edel M.J., Dick I.M., Randall A.G., Martin G.B., Prince R.L. Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats. J. Nutr. 1997, 127:1795-1799.
11. Ducy P., Schinke T., Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000, 289:1501-1504.
12. Goltzman D. Discoveries, drugs and skeletal disorders. Nat. Rev. Drug Discov. 2002, 1:784-796.
13. Hertrampf T., Gruca M.J., Seibel J., Laudenbach U., Fritzemeier K.H., Diel P. The bone-protective effect of the phytoestrogen genistein is mediated via ER alpha-dependent mechanisms and strongly enhanced by physical activity. Bone 2007, 40:1529-1535.
14. Lee S.Y., Reichlin A., Santana A., Sokol K.A., Nussenzweig M.C., Choi Y. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997, 7:703-713.
15. Liu J., Zhan M., Hannay J.A., Das P., Bolshakov S.V., Kotilingam D., Yu D., Lazar A.F., Pollock R.E., Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol. Cancer Res. 2006, 4:803-810.
16. Madrid L.V., Mayo M.W., Reuther J.Y., Baldwin A.S. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 2001, 276:18934-18940.
17. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., Tanaka S. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 2000, 148:333-342.
18. Nishida E., Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 1993, 18:128-131.
19. Picherit C., Coxam V., Bennetau-Pelissero C., Kati-Coulibaly S., Davicco M.J., Lebecque P., Barlet J.P. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J. Nutr. 2000, 130:1675-1681.
20. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
21. Soysa N.S., Alles N. NF-kappaB functions in osteoclasts. Biochem. Biophys. Res. Commun. 2009, 378:1-5.
22. Szkudelska K., Nogowski L. Genistein - a dietary compound inducing hormonal and metabolic changes. J. Steroid Biochem. Mol. Biol. 2007, 105:37-45.
23. Tang C.H., Hsu T.L., Lin W.W., Lai M.Z., Yang R.S., Hsieh S.L., Fu W.M. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem. 2007, 282:2346-2354.
24. Tang C.H., Yang R.S., Chen Y.F., Fu W.M. Basic fibroblast growth factor stimulates fibronectin expression through phospholipase C gamma, protein kinase C alpha, c-Src, NF-kappaB, and p300 pathway in osteoblasts. J. Cell. Physiol. 2007, 211:45-55.
25. Tang C.H., Huang T.H., Chang C.S., Fu W.M., Yang R.S. Water solution of onion crude powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-kappaB pathways. Osteoporos. Int. 2009, 20:93-103.
26. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
27. Tsai H.Y., Lin H.Y., Fong Y.C., Wu J.B., Chen Y.F., Tsuzuki M., Tang C.H. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Eur. J. Pharmacol. 2008, 588:124-133.
28. Tucker K.L., Hannan M.T., Chen H., Cupples L.A., Wilson P.W., Kiel D.P. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am. J. Clin. Nutr. 1999, 69:727-736.
29. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., Koga T., Martin T.J., Suda T. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:7260-7264.
30. Uesugi T., Toda T., Tsuji K., Ishida H. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, daidzin, genistin, and glycitin. Biol. Pharm. Bull. 2001, 24:368-372.
31. Wagner E.F., Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 2005, 208:126-140.
32. Wu J.B., Fong Y.C., Tsai H.Y., Chen Y.F., Tsuzuki M., Tang C.H. Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Eur. J. Pharmacol. 2008, 588:333-341.
33. Yao G.Q., Sun B., Hammond E.E., Spencer E.N., Horowitz M.C., Insogna K.L., Weir E.C. The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells. J. Biol. Chem. 1998, 273:4119-4128.
34. Yao G.Q., Wu J.J., Sun B.H., Troiano N., Mitnick M.A., Insogna K. The cell surface form of colony-stimulating factor-1 is biologically active in bone in vivo. Endocrinology 2003, 144:3677-3682.
35. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3597-3602.